Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II QL1706 plus nab-paclitaxel and bevacizumab in platinum-resistant recurrent ovarian cancer
ChiCTR2500110068Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective response rate (ORR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500110068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110068.